medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

SARS-­CoV-­2  infection  and  COVID-­19  severity  in  individuals  with  prior  seasonal  
coronavirus  infection  
  
Saurabh  Gombar1,  Timothy  Bergquist2,  Vikas  Pejaver2,  Noah  E.  Hammarlund2,  
Kanagavel  Murugesan1,  Sean  Mooney2,  Nigam  Shah3,  Benjamin  A.  Pinsky1,4,5,  
Niaz  Banaei1,4,6  
  
1  

Department  of  Pathology,  Stanford  University  School  of  Medicine,  Stanford,  CA,  

USA  
2  

Department   of   Biomedical   Informatics   and   Medical   Education,   University   of  

Washington  School  of  Medicine,  Seattle,  WA,  USA  
3  

Division  of  Biomedical  Informatics,  Department  of  Medicine,  Stanford  University  

School  of  Medicine,  Stanford,  CA,  USA  
4  

Division   of   Infectious   Diseases   and   Geographic   Medicine,   Department   of  

Medicine,  Stanford  University  School  of  Medicine,  Stanford,  CA,  USA  
5  

Clinical  Virology  Laboratory,  Stanford  Health  Care,  Stanford,  CA,  USA  

6  

Clinical  Microbiology  Laboratory,  Stanford  Health  Care,  Stanford,  CA,  USA  

  
*Corresponding  Author:    
Niaz  Banaei,  MD    
3375  Hillview  Ave,  Rm.  1602,  
Palo  Alto,  Ca  94304  
Phone  650-­736-­8052  

	  

1	  

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Fax  650-­725-­5671  
nbanaei@stanford.edu  
  
  
  

	  

  

2	  

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Abstract  
A  sizable  fraction  of  healthy  blood  donors  have  cross-­reactive  T  cells  to  SARS-­
CoV-­2  peptides  due  to  prior  infection  with  seasonal  coronavirus.  Understanding  
the  role  of  cross-­reactive  T  cells  in  immunity  to  SARS-­CoV-­2  has  implications  for  
managing  the  COVID-­19  pandemic.  We  show  that  individuals  with  documented  
history  of  seasonal  coronavirus  have  a  similar  SARS-­CoV-­2  infection  rate  and  
COVID-­19  severity  as  those  with  no  prior  history  of  seasonal  coronavirus.  Our  
findings  suggest  prior  infection  with  seasonal  coronavirus  does  not  provide  
immunity  to  subsequent  infection  with  SARS-­CoV-­2.  
  

	  

  

3	  

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Understanding  correlates  of  protective  immunity  against  SARS-­CoV-­2  remains  a  
top  priority  for  management  of  the  COVID-­19  pandemic.  Recent  studies  have  
identified  a  durable  cross-­reactive  memory  T  cell  immune  response  to  SARS-­
CoV-­2  in  healthy  blood  donors,  including  those  who  donated  prior  to  COVID-­19  
pandemic,  which  react  with  comparable  affinity  to  seasonal  coronaviruses  (OC43,  
HKU1,  229E  and  NL63)  (1-­3).  These  cross-­reactive  T  cells  are  detected  in  20  to  
50%  of  unexposed  blood  donors  from  geographically  diverse  locations  such  as  
Germany,  Netherlands,  Singapore,  USA,  and  UK,  and  are  thought  to  represent  a  
lasting  cellular  immune  response  to  past  seasonal  coronavirus  infection  (1,  2,  4-­
6).  The  significance  of  a  pre-­existing  cross-­reactive  cellular  immune  response  to  
SARS-­CoV-­2  in  terms  of  protection  against  infection  with  SARS-­CoV-­2  and  
severity  of  COVID-­19  in  those  that  do  get  infected  remains  speculative  but  has  
great  implications  for  managing  the  pandemic  and  a  rational  vaccine  strategy  for  
the  global  community.  
To  investigate  the  impact  of  past  infection  with  seasonal  coronavirus  on  
subsequent  susceptibility  to  SARS-­CoV-­2  and  severity  of  COVID-­19,  we  
retrospectively  searched  the  electronic  health  records  of  2.9  and  5.4  million  
patients  at  Stanford  Health  Care  and  University  of  Washington,  respectively,  from  
January  1,  2016  to  October  15,  2020  to  identify  individuals  who  had  both  
seasonal  coronavirus  RT-­PCR  result  prior  to  February  1,  2020  (pre  COVID-­19  
pandemic),  and  subsequent  SARS-­CoV-­2  RT-­PCR  result  after  February  1,  2020  
(COVID-­19  pandemic).  At  least  one  positive  result,  and  the  last  negative  or  
positive  result  in  those  with  multiple  seasonal  coronavirus  RT-­PCR  results  was  

	  

4	  

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

included.  In  total  2768  individuals  (Northern  California,  n=1419;;  Washington,  n  =  
1281)  met  the  inclusion  criteria.    
In  302  patients  with  a  documented  history  of  positive  seasonal  coronavirus  test  
results,  3.3%  (10)  subsequently  tested  positive  for  SARS-­CoV-­2  compared  with  
3.1%  (77)  in  2466  patients  with  a  history  of  negative  seasonal  coronavirus  result  
(P  =  0.86,  Chi-­Square  test)  (Table  1).  Similar  results  were  obtained  when  
seasonal  coronavirus  results  were  analyzed  per  year  to  determine  if  more  recent  
infection  had  an  impact  on  SARS-­CoV-­2  positivity  rate  (Supplementary  Table).  
We  also  did  not  observe  a  higher  SARS-­CoV-­2  positivity  rate  in  patients  ≥65  vs  
<65  years  old  in  groups  with  a  history  of  either  positive  or  negative  seasonal  
coronavirus  result  (data  not  shown).  Lastly,  in  those  with  COVID-­19,  the  
proportion  of  patients  with  severe  (defined  as  hospitalized  and  intubated)  or  
moderate  (defined  as  hospitalized  but  not  intubated)  infection  was  comparable  to  
those  with  history  of  positive  and  negative  seasonal  coronavirus  test  results  
(40.0%  (4/10)  vs  48.1%  (37/77),  P  =  0.63)  (Table  2).  
Our  findings  suggest  past  infection  with  seasonal  coronavirus,  and  thus  by  
inference  cross-­reactive  memory  T  cell  immune  response  to  SARS-­CoV-­2,  do  
not  provide  protective  immunity  against  subsequent  infection  with  SARS-­CoV-­2  
infection  and  also  do  not  modulate  the  severity  of  COVID-­19  in  those  that  get  
infected  by  SARS-­CoV-­2.  Our  findings  are  consistent  with  the  lack  of  protection  
against  SARS-­CoV-­2  infection  in  children  with  prior  infection  with  seasonal  
coronavirus  based  on  seropositivity  (7).  Retrospective  studies  with  larger  number  
of  participants  and  prospective  studies  in  individuals  with  pre-­existing  cross-­

	  

5	  

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

reactive  memory  T  cells  are  needed  to  confirm  lack  of  protective  immunity  to  
SARS-­CoV-­2  or  modulation  of  COVID-­19  severity  in  individuals  with  pre-­existing  
cross-­reactive  T  cells  to  seasonal  coronaviruses.  
  
References  
  
1.  J.  Braun  et  al.,  SARS-­CoV-­2-­reactive  T  cells  in  healthy  donors  and  patients  
with  COVID-­19.  Nature.(2020).  
2.  N.  Le  Bert  et  al.,  SARS-­CoV-­2-­specific  T  cell  immunity  in  cases  of  COVID-­19  
and  SARS,  and  uninfected  controls.  Nature.(2020).  
3.  J.  Mateus  et  al.,  Selective  and  cross-­reactive  SARS-­CoV-­2  T  cell  epitopes  in  
unexposed  humans.  Science  (New  York,  N.  Y.  ).(2020).  
4.  A.  Grifoni  et  al.,  Targets  of  T  Cell  Responses  to  SARS-­CoV-­2  Coronavirus  in  
Humans  with  COVID-­19  Disease  and  Unexposed  Individuals.  Cell.  181,  1489-­
1501.e15  (2020).  
5.  B.  J.  Meckiff  et  al.,  Single-­Cell  Transcriptomic  Analysis  of  SARS-­CoV-­2  
Reactive  CD4  (+)  T  Cells.  Ssrn.,  3641939  (2020).  
6.  D.  Weiskopf  et  al.,  Phenotype  and  kinetics  of  SARS-­CoV-­2-­specific  T  cells  in  
COVID-­19  patients  with  acute  respiratory  distress  syndrome.  Sci.  Immunol.  5,  
10.1126/sciimmunol.abd2071  (2020).  
7.  I.  Sermet  et  al.,  Prior  infection  by  seasonal  coronaviruses  does  not  prevent  
SARS-­CoV-­2  infection  and  associated  Multisystem  Inflammatory  Syndrome  in  
children.  medRxiv  (2020).  
  

	  

  

6	  

medRxiv preprint doi: https://doi.org/10.1101/2020.12.04.20243741; this version posted December 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table  1.  SARS-­CoV-­2  RT-­PCR  positivity  rate  in  patients  with  history  of  seasonal  
coronavirus  prior  to  COVID-­19  pandemic.  

  
  

Table 2. Severity of COVID-19 in patients with history of seasonal
coronavirus prior to COVID-19 pandemic.  

  
  

	  

7	  

